



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/038,398

01/02/2002

K. Ranji Vaidyanathan

003248.00041

8382

22908 7590 02/14/2008

BANNER & WITCOFF, LTD.  
TEN SOUTH WACKER DRIVE  
SUITE 3000  
CHICAGO, IL 60606

EXAMINER

SCHILLINGER, ANN M

ART UNIT

PAPER NUMBER

3774

MAIL DATE

DELIVERY MODE

02/14/2008

PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b> 10/038,398	<b>Applicant(s)</b> VAIDYANATHAN ET AL.	
	<b>Examiner</b> ANN SCHILLINGER	<b>Art Unit</b> 3774	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 09 January 2008.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 1,2,6-13,15 and 25-39 is/are pending in the application.
- 4a) Of the above claim(s) 9 and 10 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1, 2, 6-8, 11-13, 15, 25-39 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |  |   |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)          | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____                                      |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)          | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____  | 6) <input type="checkbox"/> Other: _____                          |

## **DETAILED ACTION**

### ***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1, 2, 6-8, 27, and 39 are rejected under 35 U.S.C. 103(a) as being unpatentable over Vanderstraeten (US Pat. No. 5,789,017) in view of Klawitter et al. (US Pat. No. 4,000,525), further in further view of Lin et al. (US Pat. No. 4,645,503). Vanderstraeten discloses the following: a biomedical implant comprising: a porous structure formed from a material comprising polybutyleneterephthalate (col. 3, lines 18-21), the porous structure having a porosity between about 25% to about 70% by volume and a pore size between about 100 to about 2400 micrometers, the porous structure providing load-bearing support for natural bone structure for a period of time (col. 1, lines 20-44; col. 2, lines 15-25; col. 4, lines 36-42); and a composition for enhancing the rate of bone growth, wherein the composition comprises a biocompatible polymer material and a calcium source, and the composition coats at least a portion of the structure or fills at least a portion of the pores of the structure (col. 2, lines 39-53; col. 3, lines 18-21). However, Vanderstraeten does not disclose the specific pores sizes and porosities that are being claimed by the Applicant. Klawitter et al. discloses a ceramic implant with the pore sizes and porosities claimed in col. 1, line 45 through col. 2, line 3 and col. 3, lines 24-38 for the purpose of creating an implant with high interconnectivity to accept bone growth.

Vanderstraeten, as modified by Klawitter et al., does not disclose having different degradation rates in different parts of the implant. Lin discloses an implant with different degradation rates in col. 2, lines 46-57 and col. 5, lines 17-25 for the purpose of creating an implant with the desired physical characteristics. Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to use the claimed pore sizes and porosities and different degradation rates in order to create an implant with the desired physical characteristics and a high interconnectivity to accept bone growth.

Claims 11, 12, 13, 15, 25, 26, and 28 are rejected under 35 U.S.C. 103(a) as being unpatentable over Vanderstraeten in view of Klawitter et al. in further view of De Bruijn et al. (US Pat. No. 6,228,117). Regarding claims 11 and 25, Vanderstraeten as modified by Klawitter et al., discloses the invention substantially as claimed, however, they do not disclose the specific biocompatible polymer-ceramic composition implanted in vivo as described by the Applicant. De Bruijn et al. discloses an implant using the claimed biocompatible polymer-ceramic composition with different degradation rates in col. 1, lines 3-6 and 37-43 for the purpose of growing bone. Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to give the specific biocompatible polymer-ceramic composition in order to grow bone.

Vanderstraeten discloses the following of claim 13: the biomedical implant of claim 11 wherein the structure has a porosity between about 50% to 60% by volume (col. 2, lines 15-25) and a pore size between about 150 to about 400 micrometers (col. 4, lines 36-42).

Vanderstraeten discloses the following of claim 15: the biomedical implant of claim 11 wherein the composition for enhancing the rate of bone growth includes a calcium source (col. 2, lines 39-42).

Vanderstraeten discloses the following of claim 28: the method of claim 25 wherein the growth-enhancing composition provides a coating over at least a portion of the biocompatible substrate (col. 3, lines 18-21).

Claims 29, 31, 32, 34, 36, and 37 are rejected under 35 U.S.C. 103(a) as being anticipated by Vanderstraeten (US Pat. No. 5789017) in view of Klawitter et al. (US Pat. No. 4,000,525). Vanderstraeten discloses the following of claim 29: a biomedical implant comprising: a porous structure formed from a material comprising polybutyleneterephthalate (col. 3, lines 18-21), the porous structure having a porosity between about 25% to about 70% by volume and a pore size between about 100 to about 2400 micrometers, the porous structure providing load-bearing support for natural bone structure for a period of time (col. 1, lines 20-44; col. 2, lines 15-25; col. 4, lines 36-42); and a composition for enhancing the rate of bone growth, wherein the composition comprises a biocompatible polymer material and a calcium source, and the composition coats at least a portion of the structure or fills at least a portion of the pores of the structure (col. 2, lines 39-53; col. 3, lines 18-21). However, Vanderstraeten does not disclose the specific pores sizes and porosities that are being claimed by the Applicant. Klawitter et al. discloses a ceramic implant with the pore sizes and porosities claimed in col. 1, line 45 through col. 2, line 3 and col. 3, lines 24-38 for the purpose of creating an implant with high interconnectivity to accept bone growth. Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to modify the device of

Art Unit: 3738

Vanderstraeten to have the pore sizes and porosities of Klawitter et al. in order to create an implant with high interconnectivity to accept bone growth.

Vanderstraeten discloses the following of claim 31: the biomedical implant of claim 29, wherein the calcium source is selected from the group consisting of calcium phosphates and calcium sulfates (col. 1, lines 20-44).

Vanderstraeten discloses the following of claim 32: the biomedical implant of claim 29, wherein the composition for enhancing the rate of bone growth both coats at least a portion of the structure and fills at least a portion of the pores of the structure (col. 3, lines 18-21).

Vanderstraeten discloses the following of claim 34: a biomedical implant comprising: a porous structure formed from a material comprising polyethyletherketone (col. 2, lines 21-22; col. 3, lines 18-21), the porous structure having a porosity between about 25% to about 70% by volume (col. 2, lines 15-25) and a pore size between about 100 to about 2400 micrometers, the porous structure providing load-bearing support for natural bone structure for a period of time (col. 4, lines 36-42); and a composition for enhancing the rate of bone growth, wherein the composition comprises a biocompatible polymer material and a calcium source, and the composition coats at least a portion of the structure or fills at least a portion of the pores of the structure (col. 2, lines 39-53; col. 3, lines 18-21).

Vanderstraeten discloses the following of claim 36: the biomedical implant of claim 34, wherein the calcium source is selected from the group consisting of calcium phosphates and calcium sulfates (col. 1, lines 20-44).

Vanderstraeten discloses the following of claim 37: the biomedical implant of claim 34, wherein the composition for enhancing the rate of bone growth both coats at least a portion of the structure and fills at least a portion of the pores of the structure (col. 3, lines 18-21).

Claims 30 and 35 are rejected under 35 U.S.C. 103(a) as being unpatentable over Vanderstraeten in view of Klawitter et al., as disclosed in claims 29 and 34, in further view of De Bruijn et al. (US Pat. No. 6228117). Vanderstraeten as modified by Klawitter et al. discloses the invention substantially as claimed, however, they do not disclose the specific biocompatible polymer-ceramic composition as described by the Applicant. De Bruijn et al. discloses an implant with the claimed biocompatible polymer-ceramic composition in col. 1, lines 37-43 for the purpose of growing bone. Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to give the specific biocompatible polymer-ceramic composition in order to grow bone.

Claims 33 and 38 are rejected under 35 U.S.C. 103(a) as being unpatentable over Vanderstraeten in view of Klawitter et al., as disclosed in claims 29 and 34, in further view of Dunn et al. (US Pat. No. 4655777). Vanderstraeten, as modified by Klawitter et al., discloses the invention substantially as claimed, however, they do not disclose the use of polycaprolactone. Dunn et al. teaches the use of polycaprolactone in col. 2, lines 40-53 for the purpose of utilizing its degradation times and degree of control of degradation. Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to use polycaprolactone in order to utilize its degradation times and degree of control of degradation.

***Response to Arguments***

Applicant's arguments with respect to claims 1, 2, 6-8, 27, and 39 have been considered but are moot in view of the new ground(s) of rejection.

Applicant's arguments filed 1/9/2008 have been fully considered but they are not persuasive. Claim language in claims 29-33 and 34-38 are interpreted as a calcium source being only an origin of calcium within the implant, and the biocompatible polymer material may be from a separate material used within the implant. Hydroxyapatite is a calcium phosphate ceramic, which meets the claims' specifications. De Bruijn et al. discloses the use of a polyglycolic acid.

Regarding the Applicants arguments addressing the priority date of the claims in the present application, Applicants contend that the presentation given by Dr. Vaidyanathan would not constitute a printed publication. However, Applicant may want to provide evidence as to how Dr. Vaidyanathan's circumstances are similar to the case law cited. Additionally, there is no indication that the presentation's audience was subject to any confidentiality restrictions. Therefore, the priority date of the present invention is January 2, 2002.

***Conclusion***

**THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period



will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to ANN SCHILLINGER whose telephone number is (571)272-6652. The examiner can normally be reached on Mon. thru Fri. 9 a.m. to 4 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Corrine McDermott can be reached on (571) 272-4754. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Ann Schillinger  
February 10, 2008

/Corrine M McDermott/  
Supervisory Patent Examiner, Art Unit 3738